Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research ...

NDA Submission Status -- D-PLEX100 rolling New Drug Application was initiated with the FDA on March 30, 2026, with CMC, nonclinical, and administrative modules submitted, and the clinical module ...

Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with ...

MacroGenics agreed to sell its GMP manufacturing operations to Bora Pharmaceuticals in a deal designed to strengthen its ...

Recently, ACROBiosystems successfully held its Innovation Day at Superlab Suisse Zürich Schlieren in Zurich, Switzerland, a ...

Discover how an Ishikawa diagram identifies cause and effect in processes, aiding quality control in manufacturing and ...

Bora Pharmaceuticals Co. has agreed to acquire the GMP drug substance manufacturing operations of MacroGenics Inc. (Nasdaq: MGNX) in a transaction designed to expand Bora’s North American biologics ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and ProTgen, a biotechnology company ...

Aldevron, a Danaher company and global leader in the production of DNA, RNA and protein for genomic medicine, and Minaris, a global cell and gene therapy contract development and manufacturing ...

Regulators stress accountability: FDA and EU frameworks require sponsors to maintain oversight of CDMOs, treating outsourcing as an extension of the pharmaceutical quality system. Quality control as ...

The US Food and Drug Administration (FDA) has released a final guidance document with immediate effect advising sponsors on ...

ECO Synthesis siRNA stereochemistry data ahead of TIDES, 2026 revenue guide $72–$76M, scale-up, cash runway—read more.